LAWRENCE, Mass.—NxStage Medical released registry statistics today that show survival and transplant rates are higher among kidney disease patients using its home hemodialysis machines compared to patients using conventional, less-frequent dialysis therapies.
For the analysis, NxStage used mortality data from 2,553 patients using its System One portable dialysis machine from more than 300 dialysis centers, which amounted to 1,603 patient years of experience. The data was then compared to 2007 mortality rates reported in the U.S. Renal Data System.
Specifically, the comparison found that survival and transplant rates are higher among the NxStage patient population undergoing daily therapy compared to reported figures for conventional, less frequent dialysis treatment, according to NxStage. NxStage patients on home daily hemodialysis experienced a better than 50 percent reduction in expected mortality compared to the overall U.S. hemodialysis patient population.
The data include patients of varied size, age, vascular access type and geographic location are participating in home daily hemodialysis, indicating its broad applicability, according to NxStage.
In addition, 92 percent of the U.S. dialysis population resides within 60 miles of a center offering NxStage home hemodialysis training, and nearly 80 percent of patients are within 30 miles. NxStage said this shows that geographic barriers to initiating daily home hemodialysis are being addressed.
Visit www.nxstage.com/chronic_renal_care/registry to access the registry summary.
“The information that NxStage is making available, while not derived from a controlled study, provides a current, accurate picture of who is participating in daily home hemodialysis and a longitudinal view of the clinical outcome trends emerging from the growing use of this therapy,” Alan Hull, MD, chief medical advisor of NxStage, said in a statement. “We will continue to enhance collective knowledge about the use of daily home hemodialysis via ongoing access to our database, which will be updated on at least a semi-annual basis, as well as our concurrent efforts to definitively establish long term outcomes via initiatives such as our FREEDOM Study."